Luomalla maksuttoman Inderes-tilin, pääset käsiksi Inderesin analyysiin, voit tilata suositun aamukatsauksen ja seurata sinua kiinnostavia yhtiöitä sekä keskusteluita.
Onko sinulla jo Inderes-tili?
Follow this company like 529 other investors.
Redeye raises its long-term estimates but maintains its fair value range unchanged on the back of the Q3 2022 report. We comment on the recent order intake and investments paving the way for improved growth, profitability, and cash flow generation.
Read more and download the Research Update.
Redeye expects to make smaller forecast adjustments on the back of this Q3 report, which was in line with our expectations.
Redeye is encouraged by SDS’s business momentum, announcing its largest agreement yet. SDS expects to deliver its complete RVM suite to Sudatel Group in three markets in a deal worth SEK25m initially and >SEK6m in recurring support revenues.
Redeye reiterates its fair value range and Base Case (SEK52) following a major agreement from a new customer: a leading Saudi telecom group.
Redeye provides its comments on the Q2 2022 report.Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
Redeye provides its comments on the Q2 2022 report.
Redeye expects to mute sales expectations slightly since customer delays have impacted these. Moreover, the CEO and chairman left the company during the quarter, which reasonably should have impacted operations somewhat.
Redeye provides a short comment regarding the recent events at SDS.
Redeye adjusts its fair value range with a downward bias but continues to see meaningful upside to the share price, which was punished by the recent Q1 report.